The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis

Taifeng Du, Jiefeng Xiao, Zhaolong Qiu, Kusheng Wu

Department of Preventive Medicine, Shantou University Medical College, Shantou, Guangdong Province, China

kswu@stu.edu.cn

Abstract

Background
At present, the management of nasopharyngeal carcinoma (NPC) is mainly based on radiotherapy, but there are many radiation delivery techniques such as intensity-modulated radiotherapy (IMRT) and 2-dimensional radiotherapy (2D-RT).

Materials and methods
We searched all the eligible studies through the PubMed, Cochrane Library, Medline, and Embase. The endpoint events in meta-analysis were overall survival (OS), tumor local control including local-regional free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS), and late toxicities.

Results
A total of ten publications met the criteria and were identified through searches of the databases and references. We included 13304 patients in the meta-analysis, of whom 5212 received IMRT and 8092 were allocated to 2D-RT alone group. Compared with 2D-RT treatment, the IMRT group was associated with a better 5-year OS (OR = 1.70; 95% CI = 1.36–2.12), LRFS (OR = 2.08; 95% CI = 1.82–2.37), and PFS (OR = 1.40; 95% CI = 1.26–1.56). Additionally, the incidence of late toxicities such as late xerostomia (OR = 0.21; 95% CI = 0.09–0.51), trismus (OR = 0.16; 95% CI = 0.04–0.60), and temporal lobe neuropathy (TLN) (OR = 0.40; 95% CI = 0.24–0.67) for NPC patients in IMRT group were significantly lower than 2D-RT.

Conclusions
The meta-analysis demonstrates that IMRT provides improved long-term tumor overall survival and local control including LRFS and PFS. Additionally, IMRT yields a lower incidence of late toxicities induced by irradiation in NPC patients. Compared to 2D-RT, IMRT may be
an effective treatment for patients with NPC. Further intensive studies should be pursued to examine the association.

Background

Nasopharyngeal carcinoma (NPC) is a kind of malignant tumor that occurs in epithelial cells of nasopharynx. It is relatively rare in the world, but some regions, such as southern China, have a high incidence of up to 15–50 per 100,000[1]. The proportion of differentiated nonkeratinizing or undifferentiated carcinoma (WHO types 2 or 3) patients is higher, but the keratinizing squamous cell carcinoma or WHO type 1 was relatively lower and common in Western countries[2,3]. Due to its special anatomical location which is difficult to surgical access, and highly sensitive to radiation, radiotherapy (RT) is the primary treatment modality for locally non-disseminated NPC. While patients are treated to improve overall survival and disease-free survival, reducing acute and late toxicity and improving quality of life should be considered. In fact, the side effects of treatment largely may lead institution of treatment breaks, and then prolongs the treatment time, and ultimately generate adversely affect on the overall survival [4].

The conventional two-dimensional radiotherapy (2D-RT) was used to deliver a “tumoricidal” dose by means of laterally opposed fields until the early 1990s, which can make the disease better controlled, but be likely to cause toxicity simultaneously, including xerostomia, mucositis, hearing loss and dysphagia with its attendant sequelae, such as osteoradionecrosis. The principle of 2D-RT mainly uses shrinkage field radiation technology; the targeted field is gradually shrunk or modified to deliver the required doses[5]. The main disadvantage of the technology makes normal organs and structures such as the parotid gland compromised, but the advanced intensity-modulated radiotherapy (IMRT) is the improved way to circumvent this drawback. IMRT can deliver high doses precisely while sparing of adjacent organs at risk, cause better control and less toxicity than 2D-RT[6–8].

Compared with 2D-RT, there are many researches on the potential advantages of IMRT reflecting on its better clinical outcomes and low toxicity. Some studies have shown that NPC patients receiving IMRT treatment can achieve local control and overall survival more than 90% and 80%, respectively [9,10]. A retrospective study suggested that local relapse-free survival (LRFS) was significantly higher while the NPC patients in T1 classification received IMRT comparing with 2D-RT treatment [11]. Nevertheless, similar IMRT advantages were also reached in another prospective randomized study, LRFS did not improve in the advanced patients (T3 and T4), and it could even be said to have a driven effect [12]. A dosimetric study showed that IMRT provided better parotid gland sparing in early-stage NPC and offered better tumor coverage and normal organ sparing in locally advanced NPC because of its dosimetric advantages[13].

High survival rates are vital for improving the quality of life (QoL). Many studies have shown that IMRT treatment in NPC patients was better than 2D-RT in sparing the parotid gland, improving quality of life[14,15] and the decrease rates of temporal lobe neuropathy (TLN)[6,16]. A randomized control trial comparing QoL early stage NPC patients between 2D-RT with IMRT treatments found that IMRT treatment was superior in swallowing and speech problems after treatment[14]. However, another randomized control trial found no significant differences in the two treatments in terms of patient-reported xerostomia[6].

At present, there are two reviews on the efficacy of IMRT. Co J et al. included 3 RCTs focusing on partial oncologic outcomes at 1-year follow up and considered only xerostomia as the
early and late effect parameter[17]. Only one RCT reported the oncology outcomes in the locally advanced stage of disease[12]. The other review combined 2D-RT and 3D-RT treatments, and found the potential advantages of IMRT treatment[18]. However, the disadvantage of marginal and geographic misses should be considered in IMRT treatment[19]. Recent data from numerous retrospective studies have demonstrated a potential survival benefit from IMRT in NPC patients[20–24]. Hence, it is necessary to compare the efficacy of IMRT and 2D-RT separately. Although there are many potential advantages for IMRT treatment to NPC patients, it is still unclear whether the dosimetric improvements can be translated into clinical significantly advantages. In light of these findings, we performed a systematic review and meta-analysis of the currently available evidences to further compare the clinical oncologic outcomes and potential toxicities of intensity-modulated radiation therapy (IMRT) with 2D-RT in NPC patients.

Materials and methods
This systematic review was carried out in accordance with the Cochrane handbook, and the evidence was reported using the Preferred Reporting of Systematic Reviews and Meta-Analyses (PRISMA) guidelines[25,26] (Supporting Information, S1 Table). A prospective protocol including objectives, study selection, outcomes of interest and statistical analysis methods was also planned according to PRISMA guidelines.

Search strategy and selection criteria
We search all the pertinent published and reported clinical trials up to December 1, 2018 through the following electronic databases: Pubmed, Cochrane Library, Medline and Embase; The medical subject headings and text words used include nasopharyngeal carcinoma, intensity-modulated radiation therapy and two-dimensional radiation therapy. Among them, the details retrieved in PubMed is as follows, "Nasopharyngeal Neoplasms" [Mesh] AND "Radiotherapy, Intensity-Modulated" [Mesh] AND ("conventional radiotherapy" [All Fields] OR "two-dimensional radiotherapy" [All Fields]) AND (("0001/01/01"[PDAT]: "2018/12/01"[PDAT]) AND "humans"[MeSH Terms]). Further details of the search strategy are shown in Supporting Information, S2 Table. The local publications were identified via manual searches in professional organizations and libraries. All studies included were in English.

Studies were included if the following criteria were satisfied: (1) types of studies: RCT, or retrospective study; (2) types of participants: participants were treated by radiotherapy either primarily or combined with surgery or chemotherapy (such as neoadjuvant, concurrent, or adjuvant); (3) types of interventions: compare IMRT alone with 2D-RT for NPC patients; (4) outcomes: reported 5-year overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), local relapse-free survival (LRFS) and late radiotoxicity. If different articles involved the same study population, the study with the complete or most recent survival data was included. Studies were excluded if they met any of the following criteria: (1) editorials, commentaries, letters, and case reports; (2) the survival data could not be extracted from the research.

Data extraction. Data extraction was conducted independently by two reviewers, and the disagreements were resolved in consultation with a third reviewer. The relevant characteristics extracted from each study included author, publication year, study design, number of IMRT and 2D-RT patients, tumor stage, the radiation dose, survival outcome, and late toxicities. Survival outcomes in present study mainly include 5-year overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), local relapse-free survival (LRFS), and late radiotoxicity. These endpoints were defined as the data from the start of RT to the data of death from any
cause (OS), the first observation of local or regional recurrence or distant metastasis (PFS), the first occurrence of distant metastasis (DMFS) and the first observation of local recurrence (LRFS). Where OS is the primary endpoint and the remaining indicators are the secondary endpoints.

**Statistical analysis.** Statistical analyses including combination of statistical pooling of data and narrative synthesis of the evidence were performed using STATA 14.0 (Stata Corporation, College Station, TX). All data analyses were expressed with odd ratios (OR) with 95% confidence intervals (CI). The results were not statistically significant if the 95% CI overlap 1, otherwise is statistically significant. For survival outcomes and quality of life, IMRT could bring favorable survival to the NPC patient when the OR is greater than 1. For the analysis of toxic effects, the incidence of toxic effects of NPC patients caused by IMRT treatment is less than 2D-RT when OR less is less than 1.

The heterogeneity between studies was quantified using the Q test\[27\] and the I-squared statistic\[28\], and heterogeneity was defined as $I^2 > 50\%$ in $I^2$ metric or $P$ value $< 0.10$ in Q test. The meta-analysis was performed using a fixed effects model (the Mantel–Haenszel method) if the level of heterogeneity was acceptable ($P > 0.10$, or $P \leq 0.10$ but $I^2 \leq 50\%$), otherwise a random effects model was used for the meta-analysis. Subgroup analysis was used to explore the reasons for the existence of heterogeneity when heterogeneity exists, and sensitivity analysis is used to assess the stability of the results by excluding each study from the meta-analysis and comparing the point estimates including and excluding the study. Publication bias in the pooled analysis was examined using egger’s funnel plot\[29\], whereby asymmetries in the funnel plot showed publication bias. All $P$ value $< 0.05$ was considered statistically significant.

**Results**

**Search results and description of studies**

The search of literature on the effectiveness of IMRT versus 2D-RT for NPC yielded 169 references (Fig 1). Of these references, 33 duplicates were excluded after title review. By reviewing abstract or full-text, 117 irrelevant publications were excluded because these studies were one arm treatment studies and 3D radiotherapy studies. Full texts of 19 studies were then reviewed for eligibility. Of the 19 full articles retrieved, 1 was further excluded for comparison IMRT versus 2D-RT and 3D-RT, 2 for reviews, 2 for insufficient data, and 4 for meta-analysis. Finally, A total of 10 articles met the inclusion criteria and were entered into qualitative analysis\[6,11,12,16,20–24,30\].

The characteristics of the 10 studies are summarized in Table 1 and Table 2. We included 13304 patients in the meta-analysis, of whom 5212 received IMRT and 8092 were allocated to 2D-RT alone group. Stages I/II comprised 20.6% of the patients, and the remaining 79.4% were stage III/IV. Seven studies had evaluated the LRFS of NPC patients. DMFS data and late xerostomia data were available in 5 studies, and OS data and DMFS data in 6 studies. PFS data was available in 4 studies. Hearing loss data were in 2 studies, and TLN data and trismus data in 3 studies.

**Survival outcomes**

The IMRT group significantly improved 5-year OS in patients with NPC. The pooled OR and 95% CI for 5-year OS were 1.70 [1.36, 2.12]. As for 5-year LRFS, seven trials including 13003 patients were identified with outcome measurements. The pooled analysis showed that compared with 2D-RT, IMRT was associated with better 5-year LRFS (OR = 2.08, 95% CI:1.82–2.37). As for 5-year PFS, IMRT treatment was better than 2D-RT for NPC patients (OR = 1.40, 95% CI: 1.26–1.56). Six studies included in 5-year DMFS pooled analysis and heterogeneity
was not found among these studies ($I^2 = 17.9\%, P = 0.301$). However, there was no difference between IMRT treatment and 2D-RT treatment for 5-year DMFS (OR = 1.11, 95% CI: 0.99–1.24) (Fig 2). When stratified into each tumor stage, there were no significant differences seen in terms of 5-year DMFS in NPC. The different effectiveness of two treatments for partial stage of patients was found in 5-year OS, 5-year LRFS, and 5-year PFS (all $P< 0.05$) (Supporting Information, S3 Table).

**Late toxicities**

Severe late xerostomia is a common problem in patients with head and neck cancer, especially 2D-RT treatment. Moreover, the radiation-induced chronic toxicity affected the survival of patients. Five studies reported late xerostomia and found that IMRT reduced the risk of the toxicity compared to 2D-RT treatment for NPC patients (OR = 0.21, 95% CI: 0.09–0.51) (Fig 3).

With regard to trismus and TLN, we retrieved relevant studies and two pooled analysis indicated that the incidence of trismus and temporal lobe neuropathy induced by radiation was significantly lower in IMRT group than in 2D-RT group (OR = 0.16; 95% CI: 0.04–0.60; OR = 0.40; 95% CI: 0.24–0.67) (Fig 3). We included two studies about hearing loss, and a meta analysis showed there was no significant difference between two treatment groups (OR = 0.16; 95% CI: 0.03–1.04).

**Quality of life (QoL)**

By consulting the literature, we found two studies[14,31] that systematically assessed the quality of life of NPC patients through European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QOL-C30) and The EOTRC Quality of Life Questionnaire-Head and Neck 35 (EORTC QOL-H&N35). Pan et al. [31] showed that IMRT (n = 59) had higher mean scores in both functional and symptom scales of EORTC QLQ-C30 for stage II NPC patients than 2D-RT (n = 47). In addition, the study demonstrated
that 2D-RT adversely affected patients with regard to global QoL, symptom scales, and functional scales compared with IMRT group (all \( P < 0.001 \)).

Pow et al.\(^{[14]}\) showed that there were significant differences in scores between the two groups for the symptom item diarrhea at 2 months (\( P = 0.007 \)) post-RT and for the functional scale role functional (revised) (\( P = 0.035 \)) at 12 months after treatment, and the IMRT group had lower symptom item scores and higher functional scale scores demonstrating a better condition for NPC patients. IMRT group had lower scale scores in speech problem at 6 and 12 months post-RT and swallowing at 12 months aspects (\( P < 0.05 \)).

### Sensitivity analysis and publication bias

Heterogeneity was not found in terms of 5-year LRFS, 5-year PFS, 5-year DFS, and 5-year DMFS in the chi-square and I-square tests, and a random effect model was used when the

| Author       | Year | Country          | Study design | The stage of patients | Treatment | No. of patients (n) | Male (%) | Median age | Stage III/IV, n (%) | T3-4, n (%) | N2-3, n (%) |
|--------------|------|------------------|--------------|-----------------------|-----------|---------------------|----------|-------------|--------------------|-------------|-------------|
| Moon et al.  | 2016 | Korean           | Nonrandomized| T1-4N0-3M0            | IMRT      | 497                 | 346 (69.6) | NR          | 378(76.1)          | 214(43.0)   | 293(59.4)   |
|              |      |                  |              | 2D-RT                 |           | 350                 | 260 (74.3) | NR          | 269(76.8)          | 166(47.5)   | 187(53.4)   |
| Kam et al.   | 2007 | Hong Kong        | Randomized   | T1-2bN0-1M0           | IMRT      | 28                  | 21 (75.0)  | 45.5        | 0                  | NR          | NR          |
|              |      |                  |              | 2D-RT                 |           | 28                  | 19 (68.0)  | 50.5        | 0                  | NR          | NR          |
| Lai et al.   | 2011 | Guangzhou, China | Nonrandomized| M0                    | IMRT      | 512                 | 393 (76.8) | NR          | 344(67.2)          | 266(51.9)   | 169(33.0)   |
|              |      |                  |              | 2D-RT                 |           | 764                 | 566 (74.1) | NR          | 532(69.6)          | 437(57.2)   | 232(30.4)   |
| Peng et al.  | 2012 | Wuhan, China     | Randomized   | M0                    | IMRT      | 306                 | 221 (72.2) | 46.7        | 210(68.6)          | NR          | NR          |
|              |      |                  |              | 2D-RT                 |           | 310                 | 210 (67.7) | 44.8        | 212(68.4)          | NR          | NR          |
| Qiu et al.   | 2017 | Guangzhou, China | Nonrandomized| M0                    | IMRT      | 102                 | 74 (72.5)  | NR          | 97(95.1)           | 92(90.2)    | 67(65.7)    |
|              |      |                  |              | 2D-RT                 |           | 74                  | 55 (74.3)  | NR          | 72(97.3)           | 70(94.6)    | 48(64.9)    |
| Tang et al.  | 2015 | Guangzhou, China | Nonrandomized| M0                    | IMRT      | 540                 | 415 (76.9) | 44.5        | NR                 | 444(82.3)   | NR          |
|              |      |                  |              | 2D-RT                 |           | 512                 | 380 (74.2) | 44.5        | NR                 | 382(74.6)   | NR          |
| Zhang et al. | 2015 | Guangzhou, China | Nonrandomized| M0                    | IMRT      | 2245                | 1495 (66.6)| NR          | 1789(79.7)         | 1536(68.4)  | 902(40.2)   |
|              |      |                  |              | 2D-RT                 |           | 4836                | 3582 (74.1)| NR          | 3864(79.9)         | 3197(66.1)  | 1662(46.4)  |
| Zhou et al.  | 2013 | Guangzhou, China | Nonrandomized| M0                    | IMRT      | 506                 | NR         | NR          | NR                 | NR          | NR          |
|              |      |                  |              | 2D-RT                 |           | 747                 | NR         | NR          | NR                 | NR          | NR          |
| Zhong et al. | 2013 | Zhanjiang, China | Nonrandomized| T1-2bN0-2M0           | IMRT      | 32                  | NR         | NR          | 11(34.4)           | NR          | NR          |
|              |      |                  |              | 2D-RT                 |           | 37                  | NR         | NR          | 13(35.1)           | NR          | NR          |
| Lee et al.   | 2014 | Hong Kong        | Nonrandomized| M0                    | IMRT      | 444                 | 333 (75.0) | 52          | 408(92.0)          | 302(68.0)   | 377(85.0)   |
|              |      |                  |              | 2D-RT                 |           | 434                 | 312 (72.0) | 48          | 256(59.0)          | 161(37.0)   | 165(38.0)   |

\( n \) = number of patients; IMRT, intensity-modulated radiotherapy; 2D-RT, 2-dimensional conventional radiotherapy; NR, not report.

https://doi.org/10.1371/journal.pone.0219611.t001
heterogeneity was found in pooled analysis. We used the egger’s funnel plot to assess the publication bias for evaluation of OS, LRFS, DMFS, late xerostomia, and trismus. The egger’s test and funnel of hearing loss was not conducted due to the number of included studies of them was less than three. The funnel plot showed no publication bias in LRFS ($P = 0.800$), PFS ($P = 0.357$), DMFS ($P = 0.765$), late xerostomia ($P = 0.168$), trismus ($P = 0.563$), and TLN ($P = 0.774$) (Fig 4). We found publication bias in OS by egger’s test ($P = 0.034$). The results of the sensitivity analysis are shown in the supplementary materials (Supporting Information, S1–S7 Figs).

Discussion

Radiation therapy (RT) is widely adopted in the treatment of head and neck neoplasms, such as NPC. RT yields better conditions for patients in different sites when compared with surgery and thus is frequently used as conservative approaches. During the past decades, new RT technologies have emerged rapidly and the delivery of RT has evolved from two dimensional (2D-RT) techniques, based primarily on X-ray images and manual calculations[32], to IMRT recently, based on non-uniform radiation beam intensities to deliver an adequate dose to the target tumor while minimizing irradiation of normal tissue such as parotid, temporal lobe outside the target[33,34]. Therefore, it is vital to undertake a systematic comparison of clinical outcomes including overall survival, loco-regional control and late toxicities between IMRT treatment and 2D-RT treatment for NPC patients.

In present study, we found the effectiveness of IMRT treatment was superior to 2D-RT for NPC patients in 5-year OS (OR = 1.70; 95% CI: 1.36–2.12), 5-year LRFS (OR = 2.08; 95% CI:
1.82–2.37), and 5-year PFS (OR = 1.40; 95% CI: 1.26–1.56). There were five studies comparing the efficacy of IMRT and 2D-RT in patients with NPC in terms of disease stage stratification [11,12,20,21,35]. Peng et al. [12] showed that oncologic outcomes of NPC patients with IMRT treatment were better than 2D-RT in T4 (P = 0.05), N2 (P = 0.026), and stage III (P = 0.018) disease. Lai et al. [11] found that IMRT increased the 5-year local progression-free survival rate only in T1 stage patients (P = 0.016). Both [35] and [20] found that patients with T3–4 had higher 5-year local progression-free survival rate when receiving IMRT (P = 0.022, P = 0.018, respectively). Moreover, the result LRFS and OS rates of patients receiving IMRT would increase at all stages disease also had been found in another study [21].

Regarding the toxicity or side effects caused by radiotherapy, it is the most noteworthy because it greatly affects the quality of life of patients. Although IMRT has an advantage to deliver an adequate dose on complex tumoral targets with dose-escalation while sparing surrounding normal organs at risk, such as salivary glands and brain stem. Previous reports showed that the use of IMRT for the treatment of NPC had higher local control rates and less late toxicity than with 2D-RT [6,8,36,37]. The present study combined the evidence to compare toxicity including late xerostomia, trismus and TLN (temporal lobe neuropathy) induced by radiation and found NPC patients receiving IMRT had fewer toxicities than 2D-RT. Among these toxic effects, xerostomia is most worthy of attention in the irradiation of the
head and neck. Five studies including 1765 patients in our study demonstrated that IMRT has a significant effect in reducing the incidence of late xerostomia compared to 2D-RT (OR = 0.21; 95% CI: 0.09–0.51). Compared with the 2D-RT group, a significant overall benefit in favor of IMRT was found regarding stimulated parotid flow rate (SPFR) and stimulated whole saliva flow rate (SWSFR) in previous studies [6,14]. The improvements in the IMRT technique result in better overall survival and longer tumor control while the patient is receiving radiation therapy, but this can also increase the incidence of complications in the later stages. Trismus and TLN are common complications caused by irradiation in NPC patients. Trismus, greatly restricted mouth opening, is a common problem in head and neck neoplasm and is frequently reported in former literature [38]. The incidence of trismus varies greatly by different studies, and it range from 5% to 38% [39,40]. Previous study demonstrated that trismus may reduce the mouth’s open level because of irradiation [41], thus might cause the nutritional deficiencies of patients. We have found IMRT reduced significantly the rate of trismus in this study (OR = 0.16; 95% CI: 0.04–0.60). There were some reports showed that the temporal lobe injury caused by irradiation has become a major factor in the death of more than half of patients [42,43]. Three studies included 2747 patients compared the radiation-induced TLN for patients with NPC, and our result demonstrated that IMRT group had significantly lower incidence of TLN occurrence compared with 2D-RT group. Additionally, the advantage that

Fig 3. Forest plot of comparison between IMRT and 2D-RT for late toxicities.

https://doi.org/10.1371/journal.pone.0219611.g003
IMRT can minimize unnecessary doses to reduce risk of toxicities for the temporal lobes in patients with NPC was found in a dosimetry study [13].

Although previous reviews [17,18] have explored the differences in efficacy between the two treatments for NPC patients, there are several strengths for this study. Firstly, there is a lack of...

![Funnel plots of publication bias summary for meta-analysis of 5-year OS (A), 5-year LRFS (B), 5-year PFS (C), 5-year DMFS (D), late xerostomia (E), trismus (F), and TLN (G).](https://doi.org/10.1371/journal.pone.0219611.g004)
comprehensive review comparing the efficacy between IMRT with 2D-RT alone for NPC patients. Although Co J et al. conducted the first meta-analysis to compare the efficacy of the two modalities, the follow-up time was only one year and the conclusion of tumor outcomes came from one evidence. Secondly, in addition to the advantages of OS and LRFS found in previous study[18], we also found that IMRT was superior to 2D-RT in PFS, and no difference was found between the two treatments for DMFS. Distant metastasis remains a challenge in the treatment of NPC patients. Thirdly, since the current research is updated and the clinical evidences are inconsistency, we have merged these new studies to explore the difference of two treatments.

Present study is the first comprehensive synthesis of current evidences to compare the efficacy of IMRT and 2D-RT for patients with NPC, but there are still some limitations in the study. Firstly, present study included some non-random and retrospective studies. Inherent limitations mostly exist in observational studies, and unbalanced clinical factors and patients receiving other treatments or not inevitably result in heterogeneity, so as to affect study results. Secondly, since the lack of sufficient evidence, we did not assess the impact of chemotherapy or RT on oncology outcomes as individual studies reported them, and found the publication bias in OS. Finally, we reviewed the current literatures about the effectiveness after two treatments in different stage of NPC patients, but did not conduct stratified analysis of tumors.

**Conclusions**

This study has identified 10 comparative studies of IMRT and 2D-RT. The meta-analysis demonstrates that IMRT provides improved long-term tumor overall survival and local control including LRFS and PFS. Additionally, IMRT yields a lower incidence of late toxicities induced by irradiation in NPC patients. Compared to 2D-RT, IMRT may be an effective treatment for patients with NPC. Further intensive studies should be pursued to examine the association.

**Supporting information**

S1 Fig. The sensitivity analysis of 5-year OS. (DOC)

S2 Fig. The sensitivity analysis of 5-year LRFS. (DOC)

S3 Fig. The sensitivity analysis of 5-year PFS. (DOC)

S4 Fig. The sensitivity analysis of 5-year DMFS. (DOC)

S5 Fig. The sensitivity analysis of 5-year late xerostomia. (DOC)

S6 Fig. The sensitivity analysis of 5-year trismus. (DOC)

S7 Fig. The sensitivity analysis of 5-year TLN. (DOC)

S1 Table. The PRISMA checklist. (DOC)
Author Contributions

Data curation: Zhaolong Qiu.
Formal analysis: Taifeng Du.
Methodology: Taifeng Du.
Resources: Kusheng Wu.
Writing – original draft: Taifeng Du.
Writing – review & editing: Jiefeng Xiao.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90. https://doi.org/10.3322/caac.20107 PMID: 21296855
2. Lee N, Harris J, Garden AS, Straube W, Glisson B, et al. (2009) Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 27: 3684–3690. https://doi.org/10.1200/JCO.2008.19.9105 PMID: 19564532
3. Chen QY, Wen YF, Guo L, Liu H, Huang PY, et al. (2011) Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103: 1761–1770. https://doi.org/10.1093/jnci/djr432 PMID: 22056739
4. Kwong DL, Nichols J, Wei WI, Chua DT, Sham JS, et al. (1999) The time course of histologic remission after treatment of patients with nasopharyngeal carcinoma. Cancer 85: 1446–1453. https://doi.org/10.1002/(sici)1097-0142(19990401)85:7<1446::aid-cncr43.0.co;2-3 PMID: 10193933
5. Gluckman J, Portugal L (1995) Photodynamic therapy for cancer of the head and neck. Cancer Treat Res 74: 159–171. PMID: 7779614
6. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, et al. (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25: 4873–4879. https://doi.org/10.1200/JCO.2007.11.5501 PMID: 17971582
7. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, et al. (2002) Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53: 12–22. PMID: 12007936
8. Toledano I, Graff P, Serre A, Boisselier P, Bensadoun RJ, et al. (2012) Intensity-modulated radiotherapy in head and neck cancer: Results of the prospective study GORTEC 2004–03. Radiother Oncol 103: 57–62. https://doi.org/10.1016/j.radonc.2011.12.010 PMID: 22296746
9. Lin S, Lu JJ, Han L, Chen Q, J. P (2010) Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: Experience of 370 consecutive cases. BMC Cancer 10: 39. https://doi.org/10.1186/1471-2407-10-39 PMID: 20146823
10. Wong FC, Ng AW, Lee VH, Lui CM, Yuen KK, et al. (2010) Whole-Field Simultaneous Integrated-Boost Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 76: 138–145. https://doi.org/10.1016/j.ijrobp.2009.01.084 PMID: 19646824
11. Lai SZ, Li WF, Chen L, Luo W, Chen YY, et al. (2011) How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80: 661–668. https://doi.org/10.1016/j.ijrobp.2010.03.024 PMID: 20643517
12. Peng G, Wang T, Yang KY, Zhang S, Zhang T, et al. (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiat Oncol 104: 286–293. https://doi.org/10.1016/j.radonc.2012.08.013 PMID: 22995588
13. Kam MK, Chau RM, Suen J, Choi PH, Teo PM (2003) Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation ☆. Int J Radiat Oncol Biol Phys 56: 145–157. PMID: 12694833

14. Pow EHN, Kwong DLW, Mcmillan AS, Wong MCM, Sham JST, et al. (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66: 981–991. https://doi.org/10.1016/j.ijrobp.2006.06.013 PMID: 17145528

15. Chen YY, Zhao C, Wang J, Ma HL, Lai SZ, et al. (2011) Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with >5 years of follow-up. Cancer 117: 2910–2916. https://doi.org/10.1002/cncr.25773 PMID: 21264821

16. Zhou GQ, Yu XL, Chen M, Guo R, Lei Y, et al. (2013) Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy. Plos One 8: e67488. https://doi.org/10.1371/journal.pone.0067488 PMID: 23974422

17. Co J, Mejia MB, Dizon JM (2016) Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature. Head Neck 38: E2130–E2142. https://doi.org/10.1002/hed.23977 PMID: 25546181

18. Zhang B, Mo Z, Du W, Wang Y, Liu L, et al. (2015) Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. Oral Oncol 51: 1041–1046. https://doi.org/10.1016/j.oraloncology.2015.08.005 PMID: 26299027

19. Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, et al. (2013) Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11: 917–923. PMID: 23964171

20. Moon SH, Cho KH, Lee CG, Keum KC, Kim YS, et al. (2016) IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma: Survival outcome in a Korean multi-institutional retrospective study (KROG 11–06). Strahlenther Onkol 192: 377–385. https://doi.org/10.1007/s00066-016-0959-y PMID: 26972085

21. Zhang MX, Li J, Shen GP, Zou X, Xu JJ, et al. (2015) Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. Eur J Cancer 51: 2587–2595. https://doi.org/10.1016/j.ejca.2015.08.006 PMID: 26318726

22. Qiu WZ, Peng XS, Xia HQ, Huang PY, Guo X, et al. (2017) A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma. J Cancer Res Clin Oncol 143: 1563–1572. https://doi.org/10.1007/s00432-017-2401-y PMID: 28342002

23. Tang LL, Chen L, Mao YP, Li WF, Sun Y, et al. (2015) Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. Radiother Oncol 116: 167–173. https://doi.org/10.1016/j.radonc.2015.07.038 PMID: 26316395

24. Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, et al. (2014) Evolution of treatment for nasopharyngeal cancer—success and setback in the intensity-modulated radiotherapy era. Radiother Oncol 110: 377–384. https://doi.org/10.1016/j.radonc.2014.02.003 PMID: 24630534

25. Shuster JJ (2011) Review: Cochrane handbook for systematic reviews of interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors. Research Synthesis Methods 2: 126–130.

26. Moher D, Liberati A, Tetzlaff J, Altman D (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ: 339.

27. Dieste O, Fernández E, García-Martínez R, Juzgado NJ. The Risk of Using the Q Heterogeneity Estimator for Software Engineering Experiments; 2011.

28. Melsen WG, Bootsma MCJ, Rovers MM, Bonten MJM (2014) The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect 20: 123–129. https://doi.org/10.1111/1469-0691.12494 PMID: 24320992

29. Macaskill P, Walter S, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20: 641–654. https://doi.org/10.1002/sim.698 PMID: 11223905

30. Zhong H, Chen G, Lin D, G. C (2013) Comparison of side effects of intensity modulated radiotherapy and conventional radiotherapy in 69 cases with nasopharyngeal carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 27: 462–464. PMID: 23989610

31. Pan XB, Huang ST, Chen KH, Jiang YM, Ma JL, et al. (2017) Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II...
nasopharyngeal carcinoma. Oncotarget 8: 46211–46218. https://doi.org/10.18632/oncotarget.17582 PMID: 28515352

32. Bucci MK, Bevan A 3rd. RM (2005) Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond. CA Cancer J Clin 55: 117–134. PMID: 15761080

33. Lee N, Puri DR, Blanco Al, Chao KS (2007) Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck 29: 387–400. https://doi.org/10.1002/hed.20332 PMID: 16358297

34. Chen YJ, Chen SC, Wang CP, Fang YY, Lee YH, et al. (2016) Trismus, xerostomia and nutrition status in nasopharyngeal carcinoma survivors treated with radiation. Eur J Cancer Care (Engl) 25: 440–448.

35. Lee AW, Tung SY Chua DT, Ngan RK, Chappell R, Tung R, et al. (2010) Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 102: 1188–1198. https://doi.org/10.1093/jnci/djq258 PMID: 20634482

36. Su SF, Han F, Zhao C, Chen CY, Xiao WW, et al. (2012) Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiotherapy Alone. Int J Radiat Oncol Biol Phys 82: 327–333. https://doi.org/10.1016/j.ijrobp.2010.09.011 PMID: 21035959

37. Xiao WW, Huang SM, Han F, Wu SX, Lu LX, et al. (2011) Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 117: 1874–1883. https://doi.org/10.1002/cncr.25754 PMID: 21509764

38. Dijkstra PU, Kalk WWI, Roodenberg JLN (2004) Trismus in head and neck oncology: a systematic review. Oral Oncol 40: 879–889. https://doi.org/10.1016/j.oraloncology.2004.04.003 PMID: 15380165

39. Steelman R, Sokol J (1986) Quantification of trismus following irradiation of the temporomandibular joint. Mo Dent J 66: 21–23. PMID: 3465988

40. Thomas F, Ozanne F, Mamelle G, Wibault P, E (1988) Radiotherapy alone for oropharyngeal carcinomas: the role of fraction size (2 Gy vs 2.5 Gy) on local control and early and late complications. Int J Radiat Oncol Biol Phys 15: 1097–1102. PMID: 3182341

41. Dijkstra PU, Huisman PM, Roodenberg JL (2006) Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg 35: 337–342. https://doi.org/10.1016/j.ijom.2005.08.001 PMID: 16280237

42. Lee AW, Kwong DL, Leung SF, Tung SY, Sze WM, et al. (2002) Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 53: 75–85. PMID: 1200744

43. Sham J, Choy D, Kwong PW, Cheng AC, Kwong DL, et al. (1994) Radiotherapy for nasopharyngeal carcinoma; shielding the pituitary may improve therapeutic ratio. Int J Radiat Oncol Biol Phys 29: 699–704. PMID: 8040015